Immunomodulators reduce the risk of surgery and hospitalisation in Crohn's disease in a prospective European population-based inception cohort: the Epi-IBD cohort

J. Burisch , V. Andersen , S. Cukovic-Cavka , P. L. Lakatos (1) , R. d'Inca , F. Magro (2) , N. Arebi , L. Kievit , I. Kaimakliotis , D. Valpiani , K. H. Katsanos , Z. Vegh , J. F. Dahlerup , Mathurin Fumery (3, 4) , N. Pedersen , J. Halfvarson , E. Belousova , K. R. Nielsen , S. Turcan , P. Ellul (5) , L. Kupcinskas , P. Oksanen , Dana Duricova (3) , M. Giannotta , A. Goldis , V. Hernandez , R. Salupere , S. Odes , E. Langholz , P. Munkholm , Epi-Ibd Study Grp

1 Semmelweis University [Budapest]
2 Hospital de São João [Porto]
3 CHU Amiens-Picardie
4 PERITOX - Périnatalité et Risques Toxiques - UMR INERIS_I 1
5 CGIAR - Consultative Group on International Agricultural Research [CGIAR]

Domaines: Sciences du Vivant [q-bio]

J. Burisch, V. Andersen, S. Cukovic-Cavka, P. L. Lakatos, R. d'Inca, et al.. Immunomodulators reduce the risk of surgery and hospitalisation in Crohn's disease in a prospective European population-based inception cohort: the Epi-IBD cohort. Journal of Crohn's and Colitis, 2018, 12 (1), pp.S42-S43. ⟨hal-03552411⟩